Nurix Therapeutics officer proposes $142K share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Nurix Therapeutics, Inc. officer Christine Ring gave notice of a proposed sale of 8,148 common shares, with an aggregate market value of $141,693.72 and an approximate sale date of June 2, 2026. Morgan Stanley Smith Barney LLC is listed as the broker.
The notice says the shares to be sold were acquired through restricted stock unit vesting and the employee stock purchase plan. The stated acquisition periods run from May 2, 2022 through January 30, 2025 for restricted stock units, and August 11, 2020 through February 16, 2023 for employee stock purchase plan shares. Earlier sales are listed for April 2, April 30, May 1 and May 4, 2026; the April 2, May 1 and May 4 entries are labeled 10b5-1 sales.
Key Figures
Key Terms
Rule 10b5-1 regulatory
Restricted Stock Units financial
Employee Stock Purchase Plan financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What is the Rule 10b5-1 plan date in Nurix's Form 144?
AI-generated analysis. How Rhea-AI works. Not financial advice.